Start biologic DMARDs early in juvenile idiopathic arthritis: study
Disease activity is lower after a year with aggressive combined therapy approach, say researchers
13th February 2020
By Lydia Hales
Early aggressive use of biological disease-modifying antirheumatic drugs (bDMARDs) is more effective for newly diagnosed polyarticular course juvenile idiopathic arthritis (JIA) than a delayed approach, researchers say.
The authors of a single-centre study of 465 newly diagnosed, DMARD-naïve patients said the early addition of bDMARDS to conventional synthetic DMARDs (csDMARDs) appeared to reduce disease activity by six months.
The study examined the records of patients, aged
